基蛋生物科技股份有限公司 市值管理制度 基蛋生物科技股份有限公司 市值管理制度 第一章 总则 第一条 为加强基蛋生物科技股份有限公司（以下简称"公司"）市值管理， 切实推动公司投资价值提升，增强投资者回报，维护投资者利益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上 市公司监管指引第 10 号——市值管理》等法律法规、规范性文件和《公司章程》 等规定，制定本制度。 第二条 本制度所称市值管理，是指公司以提高公司质量为基础，为提升投 资者回报能力和水平而实施的战略管理行为。 第三条 市值管理的基本原则包括： （一）合规性原则：公司应当在严格遵守相关法律法规、规范性文件、自律 监管规则以及《公司章程》等内部规章制度的前提下开展市值管理工作。 （三）科学性原则：公司的市值管理有其规律，应当依其规律进行科学管理， 科学研判影响公司投资价值的关键性因素，以提升公司质量为基础开展市值管理 工作。 （四）常态性原则：公司的市值成长是一个持续的和动态的过程，公司将及 时关注资本市场及公司股价动态，常态化主动跟进开展市值管理工作。 （五）诚实守信原则：公司在市值管理活动中应当注重诚信、 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has experienced rapid sales growth of its flagship product, Siponimod, with a revenue increase of 807.96% year-on-year in H1 2025, reaching 499 million yuan. The net profit attributable to shareholders was -78.84 million yuan [7] - The revenue forecast for 2025-2027 has been revised upwards, with expected revenues of 800 million, 1.01 billion, and 1.62 billion yuan respectively, compared to previous estimates of 467 million and 1.003 billion yuan [7] - The company is actively expanding its product pipeline with next-generation dual antibodies, which are currently in various stages of clinical trials [8] Financial Summary - In H1 2025, the company achieved a revenue of 499 million yuan, with a year-on-year growth of 807.96%. The net profit attributable to shareholders was -78.84 million yuan [7] - The projected revenues for 2025, 2026, and 2027 are 800 million, 1.01 billion, and 1.62 billion yuan respectively, with year-on-year growth rates of 87.0%, 26.2%, and 60.4% [10] - The company’s gross margin is expected to remain high at around 95% for the forecast period [10] Product Development and Market Expansion - Siponimod is rapidly gaining traction in the market, with sales of approximately 169 million yuan in H1 2025, driven by its indications for moderate to severe atopic dermatitis, chronic sinusitis with nasal polyps, and seasonal allergic rhinitis [8] - The company has successfully completed overseas licensing for multiple products, generating 329 million yuan in revenue from product collaborations and licensing in H1 2025 [9]

Investment Rating - The report maintains an "Outperform" rating for the company [6][4]. Core Insights - The company's core products have seen rapid sales growth after being included in the medical insurance directory, with revenue for the first half of 2025 reaching 1.41 billion yuan, a 37.8% increase year-on-year, and commercial sales revenue of 1.40 billion yuan, up 49.2% [1][9]. - The company reported a loss of 588 million yuan for the first half of 2025, widening from a loss of 249 million yuan in the same period last year, primarily due to investment losses, increased R&D expenses, and stock incentive costs [1][9]. - The company has a strong cash reserve of approximately 7.14 billion yuan as of mid-2025, indicating a solid financial position [1][9]. Summary by Sections Clinical Development - The drug "依沃西" has achieved significant overall survival (OS) benefits in the HARMONi-A trial and has initiated 13 Phase III clinical trials, with 4 trials already showing positive results [2][15]. - Two indications for "依沃西" have been approved in China, and it is also being tested in various cancers, including colorectal and pancreatic cancers [2][15]. Pipeline and Strategy - The company is upgrading its pipeline with a focus on IO2.0 and ADC strategies, with several innovative candidates in clinical trials, including AK137 (CD73/LAG3 dual antibody) and AK138D1 (HER3 ADC) [3][17]. - The company aims to provide new treatment options through internal pipeline combinations [3][17]. Financial Forecast - The report forecasts revenues of 3.30 billion yuan, 5.20 billion yuan, and 7.90 billion yuan for 2025, 2026, and 2027, respectively, with net profits projected at 29 million yuan, 730 million yuan, and 1.79 billion yuan for the same years [4][18].

Investment Rating - The investment rating for the company is "Outperform the Market" [4][17]. Core Views - The sales of Siponimod have experienced rapid growth, with revenue reaching 499 million yuan in the first half of 2025, representing an increase of 812%. The sales of Siponimod alone accounted for 169 million yuan [7][17]. - The company reported a loss of 79 million yuan in the first half of 2025, an improvement from a loss of 337 million yuan in the same period last year. Research and development expenses increased by 9% to 360 million yuan, while sales expenses surged by 492% to 138 million yuan [7][17]. - The company has approximately 2.8 billion yuan in cash as of mid-2025 [7]. Summary by Sections Sales Growth and Product Pipeline - Siponimod was approved for market launch in September 2024 and has received approval for three indications: atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The unique indications in the nasal category are exclusive to China, which is expected to drive sales growth [13][17]. - Ongoing clinical trials for additional indications, including nodular prurigo and atopic dermatitis in adolescents and children, are in Phase 3 [13]. Future Revenue Projections - The revenue forecast for the company has been revised upwards due to successful licensing transactions, with expected revenues of 827 million yuan, 1.095 billion yuan, and 2.046 billion yuan for 2025, 2026, and 2027, respectively [17]. - The projected net profit for the parent company is expected to improve to -490 million yuan in 2025, -576 million yuan in 2026, and a profit of 53 million yuan in 2027 [17]. Clinical Development Progress - The company’s pipeline includes CMG901 (CLDN18.2 ADC), which has been licensed to AZ and is currently undergoing global registration clinical trials. Other candidates like CM512 (TSLPxIL13 bispecific antibody) are in Phase 2 trials for various indications [2][13].

Core Viewpoint - Longli Biological, which engaged in financial fraud and was delisted after nine years, has recently faced a first-instance judgment in a securities false statement liability dispute, with the court ordering compensation for 1,618 investors [1][9]. Group 1: Legal Proceedings - The first-instance judgment revealed that 1,618 plaintiffs collectively hold investment loss claims amounting to 274 million yuan and legal fees of 809,000 yuan against Longli Biological [6]. - The defendant Cheng Shaobo is jointly liable for the debts owed by Longli Biological, while other defendants share joint liability within a certain percentage range, with Guolian Minsheng Securities bearing 5% of the joint liability [6][4]. Group 2: Company Background and Fraud Details - Longli Biological, established in June 2001, produces functional sugars and starches from corn and has been involved in biomass comprehensive utilization [7]. - The company was listed on the Shenzhen Stock Exchange in 2011, with Huaying Securities as its sponsor [7]. - Longli Biological faced delisting due to negative net assets for two consecutive years (2017 and 2018) and received audit reports that could not express an opinion, leading to its stock suspension in May 2019 and formal delisting in July 2020 [7][8]. Group 3: Regulatory Actions - In January 2018, the China Securities Regulatory Commission (CSRC) initiated an investigation into Longli Biological for suspected information disclosure violations [8]. - The CSRC identified Longli Biological as a typical case of financial fraud, revealing that from 2015 to mid-2017, the company inflated assets by nearly 500 million yuan, reduced liabilities by over 1.7 billion yuan, and inflated profits by approximately 140 million yuan [8]. - In January 2021, the CSRC issued administrative penalties against Longli Biological, including a fine of 600,000 yuan and a 1.5 million yuan fine against its actual controller Cheng Shaobo [8].

Core Viewpoint - The report highlights the financial performance and strategic developments of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. for the first half of 2025, emphasizing significant revenue growth, increased net profit, and advancements in drug development, particularly in the field of autoimmune diseases. Financial Performance - The company achieved a revenue of RMB 642.01 million, representing a 7.61% increase compared to RMB 596.62 million in the same period last year [4] - The net profit attributable to shareholders reached RMB 190.32 million, a substantial increase of 46.96% from RMB 129.51 million year-on-year [4] - The net cash flow from operating activities was RMB 187.73 million, up 33.95% from RMB 140.15 million in the previous year [4] - Basic earnings per share increased to RMB 0.31, a rise of 47.62% from RMB 0.21 [4] Research and Development - R&D expenses increased by 25.53%, with R&D costs accounting for 36.48% of revenue, reflecting the company's commitment to innovation [4][9] - The company has made significant progress in its clinical pipeline, with multiple core autoimmune drug projects advancing to later clinical stages [10] Market and Industry Trends - The global autoimmune disease market is projected to grow from USD 138.9 billion in 2024 to USD 192.3 billion by 2032, with biologics expected to account for 82.4% of the market [6] - In China, the autoimmune disease market is anticipated to reach USD 6.6 billion in 2025, growing at a rate of 29.4% year-on-year, with biologics comprising 51.4% of the market [8] - The company is positioned to benefit from the increasing prevalence of autoimmune diseases and the shift towards biologics and targeted therapies [7][8] Strategic Developments - The company entered a landmark licensing agreement with Pfizer, marking a significant milestone in the global positioning of Chinese pharmaceutical companies [7][9] - This agreement includes a non-refundable upfront payment of USD 1.25 billion and potential milestone payments totaling up to USD 4.8 billion, showcasing the value of Chinese innovation in the global market [9] Clinical Advancements - The company has submitted an NDA for its anti-IL-1β monoclonal antibody and has several projects progressing through clinical trials, including anti-IL-17A and anti-IL-4Rα monoclonal antibodies [10] - These advancements indicate the company's strong pipeline and its potential to address unmet clinical needs in the autoimmune disease space [10]

三生国健药业（上海）股份有限公司 募集资金管理制度 第一章 总则 第六条 保荐机构或者独立财务顾问应当按照《证券发行上市保荐业务管理 办法》 《上市规则》、本制度的规定，对公司募集资金的管理和使用履行持续督导 职责，公司应当予以配合。 第一条 为了规范三生国健药业（上海）股份有限公司（以下简称"公司"） 募集资金的管理和使用，保护投资者的权益，依照《中华人民共和国公司法》 （以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募 集资金监管规则》等有关法律法规及规范性文件的规定，结合公司实际情况，特 制定本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向 投资者募集并用于特定用途的资金监管，但不包括公司为实施股权激励计划募集 的资金监管。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新 ...

Core Viewpoint - The internal audit system of Sanofi (Shanghai) Co., Ltd. aims to enhance management and supervision of internal departments, subsidiaries, and significant affiliates, ensuring compliance with laws and regulations while improving audit quality [1][2]. Group 1: Internal Audit Definition and Objectives - Internal audit is defined as an evaluation activity conducted by internal personnel to assess the effectiveness of internal controls, risk management, and the authenticity of financial information [2][3]. - The objectives of internal control include compliance with laws, safeguarding assets, and ensuring the accuracy and completeness of information disclosure [3][4]. Group 2: Internal Audit Department Structure - The company has established an independent internal audit department that reports directly to the board's audit committee [3][5]. - The internal audit department must have a minimum of three dedicated audit personnel, with the head being a full-time position nominated by the audit committee [3][6]. Group 3: Audit Responsibilities - The internal audit department is responsible for evaluating the completeness and effectiveness of internal control systems across the company and its subsidiaries [5][10]. - It must conduct audits on financial data, ensuring legality, compliance, and authenticity, including financial reports and performance forecasts [5][10]. Group 4: Audit Procedures - The internal audit process includes planning, notifying the audited unit, collecting evidence, and drafting audit reports [8][9]. - Audit reports must be submitted within ten days after the audit's conclusion, allowing the audited unit to provide feedback [9][10]. Group 5: Internal Control Evaluation - The internal audit department is required to submit an annual internal control evaluation report to the audit committee, detailing the effectiveness of internal controls [10][11]. - If significant deficiencies or risks are identified, the audit committee must be promptly informed [11][12]. Group 6: Compliance and Reporting - The company must disclose any significant internal control deficiencies or risks to the stock exchange and provide details on corrective measures taken [11][12]. - The internal audit department must audit significant external investments, asset purchases, and guarantees to ensure compliance with regulations [12][13]. Group 7: Training and Accountability - The internal audit department is responsible for training and evaluating audit personnel to enhance their professional skills [33][34]. - Any misconduct by audit personnel, such as leaking confidential information or providing false reports, will result in disciplinary actions [34][35].

Core Viewpoint - The document outlines the information disclosure management measures for Sanofi Health Industry (Shanghai) Co., Ltd., emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of shareholders and the public [1]. Group 1: General Principles of Information Disclosure - The company must disclose all information that could significantly impact the trading price of its stocks or investment decisions [6][7]. - Information must be disclosed in a timely, fair, and accurate manner, ensuring clarity and avoiding misleading statements [7][8]. - All investors should have equal access to disclosed information, preventing selective disclosure [11]. Group 2: Responsibilities and Obligations - The chairman of the board is the primary responsible person for information disclosure, while the board secretary is responsible for its execution [2]. - All related parties, including directors, senior management, and shareholders, have disclosure obligations [2][3]. - The company must ensure that any public commitments made by related parties are disclosed promptly [3]. Group 3: Disclosure of Major Events - Major events must be disclosed immediately upon the board's resolution or when relevant parties sign agreements [12]. - If a major event is uncertain, the company may delay disclosure but must do so at the latest when a final decision is made [12]. - The company must disclose any significant changes to previously disclosed matters that could impact stock prices [14]. Group 4: Content of Disclosure - The company must disclose information reflecting its business, technology, finance, governance, competitive advantages, industry trends, and policy impacts [6]. - Regular disclosures should include annual, semi-annual, and quarterly reports, detailing financial data and significant events [30][31]. - The company must provide detailed explanations for any significant declines in net profit or revenue [26]. Group 5: Industry Information and Risks - The company should proactively disclose industry information that could significantly affect stock prices or investor decisions [59]. - It must identify and disclose risks that could adversely impact its core competitiveness and operational activities [64][65]. - Any major changes in the industry environment or operational risks must be disclosed promptly [67].

Core Points - The article outlines the independent director system of Sanofi (Shanghai) Pharmaceutical Co., Ltd, emphasizing the importance of independent directors in enhancing corporate governance and protecting minority shareholders' rights [1][2][3] Group 1: Independent Director Definition and Responsibilities - Independent directors must not hold any other positions within the company and should have no direct or indirect interests that could affect their independent judgment [1][2] - They are responsible for participating in decision-making, supervising potential conflicts of interest, and providing professional advice to enhance the board's decision-making quality [20][21] Group 2: Qualifications and Conditions for Independent Directors - Candidates for independent directors must meet specific legal and regulatory requirements, including independence from the company and its major shareholders [7][8] - Independent directors should have relevant experience, such as at least five years in legal, accounting, or economic fields, and must not have any significant negative records [10][11] Group 3: Nomination and Election Process - Independent directors can be nominated by the board or shareholders holding more than 1% of the company's shares, and the nomination must be free from conflicts of interest [13][14] - The election of independent directors requires a cumulative voting system when electing multiple directors, ensuring transparency and representation of minority shareholders [16][17] Group 4: Duties and Powers of Independent Directors - Independent directors have the authority to independently hire external consultants for audits or advice, propose meetings, and express independent opinions on matters that may harm the company or minority shareholders [21][22] - They are required to attend board meetings and can delegate their voting rights to other independent directors if unable to attend [27][28] Group 5: Reporting and Communication - Independent directors must submit annual reports detailing their attendance, participation in committees, and communication with minority shareholders [35][36] - They are also responsible for reporting any violations of laws or regulations to the board and can escalate issues to regulatory authorities if necessary [10][17] Group 6: Compensation and Support - The company is responsible for covering the costs incurred by independent directors in fulfilling their duties, including hiring professional services [40] - Independent directors receive appropriate compensation, which must be approved by the board and disclosed in the annual report [41][42]